Up a level |
Munir, Talha, Cairns, David A, Bloor, Adrian, Allsup, David, Cwynarski, Kate, Pettitt, Andrew ORCID: 0000-0002-0907-8950, Paneesha, Shankara, Fox, Christopher P, Eyre, Toby A, Forconi, Francesco ORCID: 0000-0002-2211-1831 et al (show 23 more authors)
(2024)
Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease.
The New England journal of medicine, 390 (4).
pp. 326-337.
Coen, Oliver, Corrie, Pippa, Marshall, Helen, Plummer, Ruth, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Hook, Jane, Bell, Sue, Sagoo, Gurdeep S, Meads, David, Bestall, Janine et al (show 10 more authors)
(2021)
The DANTE trial protocol: a randomised phase III trial to evaluate the Duration of ANti-PD-1 monoclonal antibody Treatment in patients with metastatic mElanoma.
BMC CANCER, 21 (1).
761-.
Love, Sharon B, Cafferty, Fay, Snowdon, Claire, Carty, Karen, Savage, Joshua, Pallmann, Philip, McParland, Lucy, Brown, Louise, Masters, Lindsey, Schiavone, Francesca et al (show 26 more authors)
(2022)
Practical guidance for running late-phase platform protocols for clinical trials: lessons from experienced UK clinical trials units.
Trials, 23 (1).
p. 757.
Danson, Sarah, Plummer, Ruth, Ottensmeier, Christian ORCID: 0000-0003-3619-1657, Hook, Jane, Marshall, Helen, Sagoo, Gurdeep, Meads, David, Bestall, Janine, Velikova, Galina, Gallagher, Ferdia et al (show 6 more authors)
(2019)
A randomised phase III multicentre trial to evaluate the duration of anti-PD1 monoclonal antibody monotherapy in patients with metastatic melanoma (DANTE) - Stage 1 Results.
.